CClinicalTrials.gg
CompletedNCT01661426Updated Feb 22, 2023

Weight Loss Diet Study: Low Carb vs Low Fat

An interventional study of Low-Carbohydrate Diet and Low-Fat Diet in Obesity and Insulin Resistance, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The traditional weight loss diet recommended by health professionals has been a low-fat, high-carbohydrate, calorie restricted diet. This recommendation has been challenged by a number of alternative dietary strategies, particularly low-carbohydrate diets. In several recent weight loss studies insulin resistant adults had more success with low- vs. high-carbohydrate diets, in contrast to insulin sensitive adults who had either more success or comparable success with the low-fat diets. The investigators enrolled 61 people with a wide range of insulin sensitivity/resistance. After determining their insulin resistance status, the investigators will split them in the middle and randomly assign them to one of four groups for six months: (1) Low-Carbohydrate/Insulin Resistant (LC/IR); (2) Low-Carbohydrate/Insulin Sensitive (LC/IS); (3) Low-Fat/Insulin Resistant (LF/IR); and (4) Low-Fat/Insulin Sensitive (LF/IS) (15 people/group). After 6 months the participants will switch diet for the following 6 months, i.e. those randomized to the Low-Carbohydrate diet will switch to the Low-Fat diet and vice-versa. The primary outcome of this study is to determine whether weight loss success can be increased if one follows the dietary approach appropriately matched to their insulin resistance status. Secondary outcomes include fasting insulin, glucose, lipids, and fatty acid composition.

--------------------------------------------------------------------------------

Read the detailed description

The investigators hope to learn whether matching the weight loss diet to one's insulin resistance status will increase weight loss the success. The relevance of these findings is highlighted by the fact that the national recommendations for weight loss are to follow a high-carbohydrate, low-fat diet. This would imply that about half the population has been given the wrong advice in regards to the most successful dietary pattern for weight loss.

Plasma fatty acid composition patterns have been shown to be associated with both insulin resistance and/or carbohydrate intake. As secondary analyses, the investigators will explore: (1) differences in plasma fatty acid composition between insulin sensitive and resistant participants at baseline; (2) the correlations between insulin markers and plasma fatty acid composition at baseline; (3) the interaction between insulin status and diet on 6-month changes in the plasma fatty acid composition; (4) plasma fatty acid composition changes in participants on low fat and low carbohydrate diets after 6 months; and (5) the correlations between changes in insulin markers, dietary components, and plasma fatty acid composition after 6 months.

02

Conditions studied

  • Obesity
  • Insulin Resistance

Keywords

  • Adults
  • Weight loss
  • Diet
  • Insulin Resistance
  • Fatty acid composition
03

In context

Insulin Resistance

1,960 studies on the registry are indexed under Insulin Resistance; 306 are open to participants now.

This study's enrollment of 61 is above the median of 40 across 1,536 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: > or = 18 years of age
  • Women: Pre-menopausal (self-report) and \<50 years of age
  • Men: \<50 years of age
  • Race/Ethnicity: All
  • BMI (body mass index): 28-40 kg/m2 (need to lose >10% body weight to achieve healthy BMI)
  • Body weight stable for the last two months, and not actively on a weight loss plan
  • No plans to move from the area over the next 14 months
  • Available and able to participate in the evaluations and intervention for the study period
  • Willing to accept random assignment
  • To enhance study generalizability, people on medications not noted below as specific exclusions can participate if they have been stable on such medications for at least three months
  • Ability and willingness to give written informed consent
  • No known active psychiatric illness

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating, within 6 months post-partum, or planning to become pregnant in the next 12 months; no menstruation for the previous 12 months
  • Diabetes (type 1 and 2) or history of gestational diabetes or on hypoglycemic medications for any other indication
  • Prevalent diseases: Malabsorption, renal or liver disease, active neoplasms, recent myocardial infarction, hypertension (except for those stable on hypertensive medications) (\<6 months) (patient self-report and, if available, review of labs from primary care provider)
  • Smokers (because of effect on weight and lipids)
  • History of serious arrhythmias, or cerebrovascular disease
  • Uncontrolled hyper- or hypothyroidism (TSH not within normal limits)
  • Medications: Lipid lowering, diabetes medications, and those known to affect weight/energy expenditure
  • Excessive alcohol intake (self-reported, >3 drinks/day)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Low-Carbohydrate Diet first, then Low-Fat Diet (IR)

    Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.

    Behavioral: Low-Carbohydrate Diet · Behavioral: Low-Fat Diet

  • Active comparator
    Low-Fat Diet first, then Low-Carbohydrate Diet (IS)

    Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.

    Behavioral: Low-Carbohydrate Diet · Behavioral: Low-Fat Diet

Interventions

  • BehavioralLow-Carbohydrate Diet

    Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.

  • BehavioralLow-Fat Diet

    Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.

06

What researchers measure

Primary outcomes

  1. Change in weight

    Weight change was calculated as the 12 month value minus the baseline value

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change in Fasting Insulin

    Fasting insulin change was calculated as the 12 month value minus the baseline value

    Time frame: Baseline and 12 months

  2. Change in insulin AUC

    Insulin area under the curve (AUC) change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  3. Change in Fasting Glucose

    Fasting glucose change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  4. Change in LDL-Cholesterol

    LDL-cholesterol change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  5. Change in HDL-Cholesterol

    HDL-cholesterol change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  6. Change in Triglycerides

    Triglycerides change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  7. Change in systolic and diastolic blood pressure

    Blood pressure change was calculated as the 12 month value minus the baseline value.

    Time frame: Baseline and 12 months

  8. Plasma fatty acid composition at baseline

    Comparison of the plasma fatty acid composition between insulin sensitive and resistant participants at baseline.

    Time frame: Baseline

  9. Correlations between insulin markers and plasma fatty acid composition at baseline.

    Time frame: Baseline

  10. Interaction between insulin status and diet on 6-month changes in the plasma fatty acid composition.

    Time frame: 6 months

  11. Comparison of plasma fatty acid composition changes in participants on low fat and low carbohydrate diets after 6 months.

    Time frame: Baseline and 6 months

  12. Correlations between changes in insulin markers, dietary components, and plasma fatty acid composition after 6 months.

    Time frame: 6 months

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

References and documents

Publications

  • Gardner CD, Offringa LC, Hartle JC, Kapphahn K, Cherin R. Weight loss on low-fat vs. low-carbohydrate diets by insulin resistance status among overweight adults and adults with obesity: A randomized pilot trial. Obesity (Silver Spring). 2016 Jan;24(1):79-86. doi: 10.1002/oby.21331. Epub 2015 Dec 6. PubMed 26638192 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01661426
Lead sponsor
Stanford University
Collaborators
Hass Avocado Board
Responsible party
Christopher Gardner (Associate Professor of Medicine, Stanford University) — Principal investigator
First posted
Aug 9, 2012
Start date
Apr 2012
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Feb 22, 2023

Study contacts

Christopher D Gardner, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion